Real-world effectiveness of second-line Afatinib versus chemotherapy for the treatment of advanced lung squamous cell carcinoma in immunotherapy-naïve patients | BMC Cancer | Full Text
Lower starting dose of afatinib for the treatment of metastatic lung adenocarcinoma harboring exon 21 and exon 19 mutations | SpringerLink
Boehringer Ingelheim Clinic Infographics — melissamatias
Kaplan-Meier survival curves of progression-free survival in patients... | Download Scientific Diagram
Comparison of progression-free survival (PFS) and overall survival... | Download Scientific Diagram
Kaplan-Meier survival curves of progression-free survival in patients... | Download Scientific Diagram
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | NEJM
Progression-free survival and overall survival in patients with... | Download Scientific Diagram
Progression-free survival Kaplan-Meier curves for afatinib (yellow)... | Download Scientific Diagram
Behandeling patiënten met activerende EGFR-mutatie bij NSCLC - Richtlijn - Richtlijnendatabase
Behandeling patiënten met activerende EGFR-mutatie bij NSCLC - Richtlijn - Richtlijnendatabase
Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non‑small cell lung cancer in patients with common and rare EGFR gene mutations
Positieve resultaten met Giotrif® bevestigd tijdens ESMO 2016 - Info - Artsenkrant.com
The EPICAL trial, a phase Ib study combining first line afatinib with anti-EGF vaccination in EGFR-mutant metastatic NSCLC - Lung Cancer
Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study | BMC Cancer | Full Text
Afatinib, een Tyrosine kinase remmer geeft goede resultaten bij longkankerpatiënten met uitzaaiingen in de hersenen in vergelijking met chemo en placebo
Efficacy of the Irreversible ErbB Family Blocker Afatinib in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)–Pretreated Non–Small-Cell Lung Cancer Patients with Brain Metastases or Leptomeningeal Disease - ScienceDirect
Kaplan-Meier survival curves of progression-free survival in patients... | Download Scientific Diagram
Symptom and Quality of Life Benefit of Afatinib in Advanced Non–Small-Cell Lung Cancer Patients Previously Treated with Erlotinib or Gefitinib: Results of a Randomized Phase IIb/III Trial (LUX-Lung 1) - Journal of
Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer - Annals of Oncology
Progression free survival of afatinib vs gefitinib by independent... | Download Scientific Diagram
TÓM TẮT LÝ LỊCH TRÍCH NGANG GS SUMITRA THONGPRASERT -Nơi công tác hiện tai: Trường Đại Học Chiang Mai, Thái Lan. -Chuyên ngành: ung thư. -GS là chủ tịch. - ppt download
Kaplan-Meier survival curves of progression-free survival in patients... | Download Scientific Diagram
Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study | BMC Cancer | Full Text
Efficacy of the Irreversible ErbB Family Blocker Afatinib in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)–Pretreated Non–Small-Cell Lung Cancer Patients with Brain Metastases or Leptomeningeal Disease - Journal of Thoracic
InOncology | LUX-Lung 3 Clinical Trial | Afatinib NSCLC Trials & Studies | Boehringer Ingelheim
A) Overall survival of sequential therapy for afatinib followed by... | Download Scientific Diagram
